Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) Shares Sold by Bellevue Group AG

Bellevue Group AG reduced its stake in shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) by 97.4% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 15,100 shares of the specialty pharmaceutical company’s stock after selling 565,500 shares during the period. Bellevue Group AG’s holdings in Supernus Pharmaceuticals were worth $437,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also modified their holdings of the company. Quadrant Capital Group LLC boosted its holdings in shares of Supernus Pharmaceuticals by 1,117.6% in the 4th quarter. Quadrant Capital Group LLC now owns 1,449 shares of the specialty pharmaceutical company’s stock valued at $42,000 after buying an additional 1,330 shares during the period. Covestor Ltd boosted its holdings in shares of Supernus Pharmaceuticals by 115.0% in the 3rd quarter. Covestor Ltd now owns 2,350 shares of the specialty pharmaceutical company’s stock valued at $65,000 after buying an additional 1,257 shares during the period. China Universal Asset Management Co. Ltd. boosted its holdings in shares of Supernus Pharmaceuticals by 350.7% in the 4th quarter. China Universal Asset Management Co. Ltd. now owns 6,314 shares of the specialty pharmaceutical company’s stock valued at $183,000 after buying an additional 4,913 shares during the period. Envestnet Portfolio Solutions Inc. acquired a new position in shares of Supernus Pharmaceuticals in the 3rd quarter valued at about $262,000. Finally, Profund Advisors LLC lifted its position in Supernus Pharmaceuticals by 17.7% in the 3rd quarter. Profund Advisors LLC now owns 9,660 shares of the specialty pharmaceutical company’s stock valued at $266,000 after purchasing an additional 1,454 shares during the last quarter.

Supernus Pharmaceuticals Trading Down 1.6 %

SUPN stock opened at $25.77 on Tuesday. Supernus Pharmaceuticals, Inc. has a 52 week low of $21.99 and a 52 week high of $35.44. The company has a market capitalization of $1.42 billion, a price-to-earnings ratio of -90.31 and a beta of 0.93. The firm’s 50-day moving average is $29.62 and its two-hundred day moving average is $29.35.

Insiders Place Their Bets

In other Supernus Pharmaceuticals news, VP Padmanabh P. Bhatt sold 14,491 shares of the business’s stock in a transaction dated Thursday, March 21st. The shares were sold at an average price of $35.31, for a total transaction of $511,677.21. Following the sale, the vice president now directly owns 8,570 shares in the company, valued at approximately $302,606.70. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. In other Supernus Pharmaceuticals news, VP Padmanabh P. Bhatt sold 12,364 shares of the business’s stock in a transaction dated Tuesday, March 19th. The shares were sold at an average price of $35.31, for a total transaction of $436,572.84. Following the sale, the vice president now directly owns 8,570 shares in the company, valued at approximately $302,606.70. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, VP Padmanabh P. Bhatt sold 14,491 shares of the business’s stock in a transaction dated Thursday, March 21st. The stock was sold at an average price of $35.31, for a total transaction of $511,677.21. Following the sale, the vice president now owns 8,570 shares in the company, valued at $302,606.70. The disclosure for this sale can be found here. 8.76% of the stock is owned by insiders.

Analysts Set New Price Targets

Separately, Piper Sandler cut their price objective on shares of Supernus Pharmaceuticals from $45.00 to $41.00 and set an “overweight” rating on the stock in a research report on Wednesday, February 28th.

Supernus Pharmaceuticals Profile

Supernus Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age.